177 related articles for article (PubMed ID: 8805928)
1. Superiority of cisplatin or carboplatin in combination with teniposide and vincristine in the induction chemotherapy of small-cell lung cancer. A randomized trial with 5 years follow up.
Lassen U; Kristjansen PE; Osterlind K; Bergman B; Sigsgaard TC; Hirsch FR; Hansen M; Dombernowsky P; Hansen HH
Ann Oncol; 1996 Apr; 7(4):365-71. PubMed ID: 8805928
[TBL] [Abstract][Full Text] [Related]
2. Quality versus quantity of life in the treatment of patients with advanced small-cell lung cancer? A randomized phase III comparison of weekly carboplatin and teniposide versus cisplatin, adriamycin, etoposide alternating with cyclophosphamide, methotrexate, vincristine and lomustine. Swiss Group for Clinical Cancer Research (SAKK).
Joss RA; Alberto P; Hürny C; Bacchi M; Leyvraz S; Thürlimann B; Cerny T; Martinelli G; Stahel R; Ludwig C
Ann Oncol; 1995 Jan; 6(1):41-8. PubMed ID: 7536028
[TBL] [Abstract][Full Text] [Related]
3. Superiority of high-dose platinum (cisplatin and carboplatin) compared to carboplatin alone in combination chemotherapy for small-cell lung carcinoma: a prospective randomised trial of 280 consecutive patients.
Hirsch FR; Osterlind K; Jeppesen N; Dombernowsky P; Ingeberg S; Sorensen PG; Kristensen C; Hansen HH
Ann Oncol; 2001 May; 12(5):647-53. PubMed ID: 11432623
[TBL] [Abstract][Full Text] [Related]
4. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up.
Sundstrøm S; Bremnes RM; Kaasa S; Aasebø U; Hatlevoll R; Dahle R; Boye N; Wang M; Vigander T; Vilsvik J; Skovlund E; Hannisdal E; Aamdal S;
J Clin Oncol; 2002 Dec; 20(24):4665-72. PubMed ID: 12488411
[TBL] [Abstract][Full Text] [Related]
5. Phase II and III studies with carboplatin in small cell lung cancer.
Gatzemeier U; Hossfeld DK; Neuhauss R; Reck M; Achterrath W; Lenaz L
Semin Oncol; 1992 Feb; 19(1 Suppl 2):28-36. PubMed ID: 1329220
[TBL] [Abstract][Full Text] [Related]
6. Small cell lung cancer (SCLC): a randomized trial of cyclophosphamide, adriamycin, vincristine plus etoposide (CAV-E) or teniposide (CAV-T) as induction treatment, followed in complete responders by alpha-interferon or no treatment, as maintenance therapy.
Tummarello D; Graziano F; Mari D; Cetto G; Pasini F; Antonio S; Isidori P; Gasparini S
Anticancer Res; 1994; 14(5B):2221-7. PubMed ID: 7840527
[TBL] [Abstract][Full Text] [Related]
7. A randomized, controlled phase III study of cyclophosphamide, doxorubicin, and vincristine with etoposide (CAV-E) or teniposide (CAV-T), followed by recombinant interferon-alpha maintenance therapy or observation, in small cell lung carcinoma patients with complete responses.
Tummarello D; Mari D; Graziano F; Isidori P; Cetto G; Pasini F; Santo A; Cellerino R
Cancer; 1997 Dec; 80(12):2222-9. PubMed ID: 9404698
[TBL] [Abstract][Full Text] [Related]
8. Early versus late alternating chemotherapy in small-cell lung cancer. Swiss Group for Clinical Cancer Research (SAKK).
Joss RA; Bacchi M; Hürny C; Bernhard J; Cerny T; Martinelli G; Leyvraz S; Senn HJ; Stahel R; Siegenthaler P
Ann Oncol; 1995 Feb; 6(2):157-66. PubMed ID: 7786823
[TBL] [Abstract][Full Text] [Related]
9. Carboplatin in small cell lung cancer.
Gatzemeier U; Hossfeld DK; Neuhauss R; Reck M; Achterrath W; Lenaz L
Semin Oncol; 1991 Feb; 18(1 Suppl 2):8-16. PubMed ID: 1846981
[TBL] [Abstract][Full Text] [Related]
10. Randomized phase II study of cyclophosphamide, doxorubicin, and vincristine compared with single-agent carboplatin in patients with poor prognosis small cell lung carcinoma.
White SC; Lorigan P; Middleton MR; Anderson H; Valle J; Summers Y; Burt PA; Arance A; Stout R; Thatcher N
Cancer; 2001 Aug; 92(3):601-8. PubMed ID: 11505405
[TBL] [Abstract][Full Text] [Related]
11. Combination chemotherapy of limited-stage small-cell lung cancer. A controlled trial on 221 patients comparing two alternating regimens.
Osterlind K; Hansen M; Hirsch FR; Dombernowsky P; Sörenson S; Pedersen AG; Hansen HH
Ann Oncol; 1991 Jan; 2(1):41-6. PubMed ID: 1848996
[TBL] [Abstract][Full Text] [Related]
12. Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: a randomized phase III study of the Cancer and Leukemia Group B.
Miller AA; Herndon JE; Hollis DR; Ellerton J; Langleben A; Richards F; Green MR
J Clin Oncol; 1995 Aug; 13(8):1871-9. PubMed ID: 7636529
[TBL] [Abstract][Full Text] [Related]
13. Randomized phase III trial of paclitaxel, etoposide, and carboplatin versus carboplatin, etoposide, and vincristine in patients with small-cell lung cancer.
Reck M; von Pawel J; Macha HN; Kaukel E; Deppermann KM; Bonnet R; Ulm K; Hessler S; Gatzemeier U
J Natl Cancer Inst; 2003 Aug; 95(15):1118-27. PubMed ID: 12902441
[TBL] [Abstract][Full Text] [Related]
14. Treatment of limited small-cell lung cancer with etoposide and cisplatin alternating with vincristine, doxorubicin, and cyclophosphamide versus concurrent etoposide, vincristine, doxorubicin, and cyclophosphamide and chest radiotherapy: a Southwest Oncology Group Study.
Goodman GE; Crowley JJ; Blasko JC; Livingston RB; Beck TM; Demattia MD; Bukowski RM
J Clin Oncol; 1990 Jan; 8(1):39-47. PubMed ID: 2153194
[TBL] [Abstract][Full Text] [Related]
15. Alternating versus sequential chemotherapy in small cell lung cancer. A randomized German multicenter trial.
Havemann K; Wolf M; Holle R; Gropp C; Drings P; Manke HG; Hans K; Schroeder M; Heim M; Victor N
Cancer; 1987 Mar; 59(6):1072-82. PubMed ID: 3028596
[TBL] [Abstract][Full Text] [Related]
16. Combined-modality treatment of small-cell lung cancer: randomized comparison of three induction chemotherapies followed by maintenance chemotherapy with or without radiotherapy to the chest. Swiss Group for Clinical Cancer Research (SAKK).
Joss RA; Alberto P; Bleher EA; Ludwig C; Siegenthaler P; Martinelli G; Sauter C; Schatzmann E; Senn HJ
Ann Oncol; 1994 Dec; 5(10):921-8. PubMed ID: 7696164
[TBL] [Abstract][Full Text] [Related]
17. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group.
Roth BJ; Johnson DH; Einhorn LH; Schacter LP; Cherng NC; Cohen HJ; Crawford J; Randolph JA; Goodlow JL; Broun GO
J Clin Oncol; 1992 Feb; 10(2):282-91. PubMed ID: 1310103
[TBL] [Abstract][Full Text] [Related]
18. Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer. A Hellenic Co-operative Oncology Group study.
Skarlos DV; Samantas E; Kosmidis P; Fountzilas G; Angelidou M; Palamidas P; Mylonakis N; Provata A; Papadakis E; Klouvas G
Ann Oncol; 1994 Sep; 5(7):601-7. PubMed ID: 7993835
[TBL] [Abstract][Full Text] [Related]
19. Carboplatin/etoposide/vincristine therapy in small cell lung cancer.
Gatzemeier U; von Pawel J; Laumen R; Hossfeld DK; Neuhauss R; Reck M; Lenaz L
Oncology; 1992; 49 Suppl 1():25-33. PubMed ID: 1323809
[TBL] [Abstract][Full Text] [Related]
20. Randomized trial comparing weekly versus 3-week chemotherapy in small-cell lung cancer: a Cancer Research Campaign trial.
Souhami RL; Rudd R; Ruiz de Elvira MC; James L; Gower N; Harper PG; Tobias JS; Partridge MR; Davison AG; Trask C
J Clin Oncol; 1994 Sep; 12(9):1806-13. PubMed ID: 8083704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
